BioNTech SE - ADR

NASDAQ:BNTX   12:12:50 PM EDT
94.70
+0.61 (+0.65%)
Products

Biontech And Pfizer Initiate Rolling Submission To European Medicines Agency

Published: 10/06/2020 09:13 GMT
BioNTech SE (BNTX) - Biontech Se - Biontech and Pfizer Initiate Rolling Submission to European Medicines Agency for Sars-cov-2 Vaccine Candidate Bnt162b2.
Biontech Se - Vaccine Candidate is Currently Being Evaluated in a Global Phase 3 Study Ongoing at More Than 120 Clinical Sites Worldwide Including United States, Brazil, South Africa and Argentina.
Biontech Se - Trial Has Enrolled Approximately 37,000 Participants With More Than 28,000 Having Received Their Second Vaccinatio.